ARS Pharmaceuticals, Inc. (SPRY)

Over the past six months, ARS Pharmaceuticals' stock has experienced volatility. Key events include regulatory approvals and updates, such as the FDA approving updated prescribing information for neffy® and Health Canada granting approval for neffy®. The company reported its Q4 2025 financial results, beating EPS and revenue forecasts, but concerns were raised about the slow commercial uptake of neffy®. Analyst coverage includes Northland initiating coverage with an "Outperform" rating and Leerink Partners raising its price target. The stock has shown volatility, correlating with FDA communications, and has underperformed due to weak refill rates, payer friction, and high cash burn.

Demand for epinephrine products, including neffy®, exhibits seasonality, with the third quarter typically being the peak season for sales. ARS Pharmaceuticals aims to capitalize on this by launching direct-to-consumer marketing campaigns ahead of the "back-to-school" season. The company's commercial strategies include expanding its sales force and reducing prior authorization barriers to accelerate market share capture.

ARS Pharmaceuticals, Inc. (SPRY) is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions, including anaphylaxis. Their primary product is neffy® (epinephrine nasal spray), a needle-free intranasal epinephrine treatment approved by the FDA in August 2024 for adult and pediatric use.

ARS Pharmaceuticals has an expanding global footprint, with neffy® commercially available in the U.S. Strategic licensing agreements are in place for distribution in European markets and Canada. Regulatory approvals have been granted in the U.S., Canada, and China, with decisions anticipated in the U.K., Japan, and Australia. Neffy® has secured placement on national formularies such as OptumRx and Cigna.

ARS Pharmaceuticals' brand reputation has been shaped by the commercialization and regulatory milestones of neffy®. Positive aspects include positive patient feedback, growing payer coverage, and positive analyst outlooks. The FDA's approval of neffy® and global approvals in Canada and China have been significant positive events. Challenges include the slow commercial uptake of neffy®, high SG&A expenses, and competition from established products.

The ownership structure of ARS Pharmaceuticals (SPRY) includes institutional, insider, and retail investors. Approximately 68.16% of the stock is held by institutions, with major holders including Ra Capital Management and Orbimed Advisors. Insiders hold about 33.50% of the stock, with Sarina Tanimoto owning a significant number of shares. Retail investors hold approximately 22.09% of the company's stock.